ARS Pharmaceuticals (SPRY) Non-cash Items (2020 - 2026)

ARS Pharmaceuticals has disclosed Non-cash Items across 7 years of filings, most recently posting $35.6 million for Q1 2026.

• Non-cash Items for Q1 2026 came in at $35.6 million, down 64.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.6 million (down 64.81% YoY), and the FY2025 annual result was $78.2 million, up 9.32% from the prior year.
• Non-cash Items came in at $35.6 million for Q1 2026 at ARS Pharmaceuticals, down from $78.2 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $38.2 billion in Q2 2023 to a low of $4.5 million in Q1 2022.
• The 5-year median for Non-cash Items is $35.6 million (2026), against an average of $2.3 billion.
• Across the five-year window, Non-cash Items tumbled 99.96% in 2022 and jumped 530842.76% in 2023, its largest moves.
• ARS Pharmaceuticals' Non-cash Items stood at $4.6 million in 2022, then soared by 445.17% to $25.1 million in 2023, then soared by 185.1% to $71.5 million in 2024, then climbed by 9.32% to $78.2 million in 2025, then tumbled by 54.5% to $35.6 million in 2026.
• The last three Non-cash Items figures came in at $35.6 million (Q1 2026), $78.2 million (Q4 2025), and $48.3 million (Q3 2025), per Business Quant data.